Evaluation of a multimodal ctDNA-based assay for detection of aggressive cancers lacking standard screening tests
We identified numerous shared ctDNA signals across five common cancers and LSS cancers, demonstrating that SPOT-MAS could serve as a non-invasive method for detecting low-prevalence cancers with 96.2% specificity and 74.8% overall sensitivity, including a sensitivity of 60.7% for early-stage detection.
Effective Clinical Follow-Up for ctDNA Multi-Cancer Early Detection Test: A Peer-Reviewed Study of Post-Test Standard Operating Procedure and Real-Life Results

Cell free DNA (cfDNA)-based assays hold great potential in detecting early cancer signals. However, predicting the tissue-of-origin for multiple cancer types at an early stage remains challenging due to the low abundance of tumor- derived cfDNA and the confounding presence of various DNA components released from non- tumor sources.
Pioneering a Tumor-Specific Methylation Atlas (TSMA) to Identify Tissue of Origin (TOO) in Multi-Cancer Early Detection

Cell free DNA (cfDNA)-based assays hold great potential in detecting early cancer signals. However, predicting the tissue-of-origin for multiple cancer types at an early stage remains challenging due to the low abundance of tumor- derived cfDNA and the confounding presence of various DNA components released from non- tumor sources.